XORTX Therapeutics Inc
$ 0.38
-0.78%
25 Mar - close price
- Market Cap 2,680,500 USD
- Current Price $ 0.38
- High / Low $ 0.41 / 0.38
- Stock P/E N/A
- Book Value 0.30
- EPS -0.56
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.47 %
- ROE -0.98 %
- 52 Week High 1.41
- 52 Week Low 0.36
About
XORTX Therapeutics Inc., a biopharmaceutical company, is dedicated to the development and commercialization of therapies to treat progressive kidney disease, hypertension, insulin resistance, and diabetic nephropathy. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$14.04
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-02 | 2025-11-13 | 2025-08-15 | 2025-05-14 | 2025-03-25 | 2024-11-12 | 2024-08-14 | 2024-05-15 | 2023-12-31 | 2023-11-14 | 2023-08-14 | 2023-05-15 |
| Reported EPS | -0.0951 | -0.1337 | -0.19 | 0.04 | -0.81 | -0.2022 | 0.0586 | 1.3504 | -0.636 | -0.67 | -0.8 | -0.11 |
| Estimated EPS | -0.316 | -0.316 | None | None | -0.41 | None | -0.923 | -0.2767 | -0.815 | -0.19 | -1.36 | -0.1456 |
| Surprise | 0.2209 | 0.1823 | 0 | 0 | -0.4 | 0 | 0.9816 | 1.6271 | 0.179 | -0.48 | 0.56 | 0.0356 |
| Surprise Percentage | 69.9051% | 57.6899% | None% | None% | -97.561% | None% | 106.3489% | 588.0376% | 21.9632% | -252.6316% | 41.1765% | 24.4505% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.08 | $0.07 | $0.08 | $0.08 | $0.08 | $0.07 | $0.07 | $0.07 | $0.05 | $0.05 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XRTX
2026-03-24 22:09:06
XORTX Therapeutics Inc. (OTCQB:XRTX) (NASDAQ:XRTX) announced that its shareholders have approved a share consolidation at a ratio of up to 5-for-1 to maintain its Nasdaq listing. The company did not specify the exact ratio or the effective date, leaving the board to determine these details. This move follows a previous warning from Nasdaq regarding non-compliance with the minimum bid price requirement.
2026-03-24 21:09:06
XORTX Therapeutics shareholders have approved a share consolidation of up to 5-for-1, aimed at meeting NASDAQ's requirement for shares to trade above $1.00. The consolidation will reduce the number of issued common shares from 6,962,218 to approximately 1,392,443. This move is subject to TSX Venture Exchange approval and is intended to ensure continued listing on NASDAQ.
2026-03-24 21:09:06
XORTX Therapeutics Inc. announced that its shareholders approved a share consolidation at the annual general meeting on March 24, 2026. This consolidation, on a basis of up to five pre-consolidation shares for every one post-consolidation share, aims to help the company maintain compliance with NASDAQ's listing requirements, specifically the $1.00 minimum share price. The company expects the total number of outstanding shares to be approximately 1,392,443 after the consolidation, pending TSX Venture Exchange approval.
2026-03-24 21:09:06
XORTX Therapeutics shareholders have approved a share consolidation, allowing the board to combine up to five existing common shares into one. This move aims to help the company maintain compliance with Nasdaq's listing requirements, specifically the $1.00 minimum bid price. The consolidation, pending TSX Venture Exchange approval, could reduce outstanding shares from 6,962,218 to approximately 1,392,443.
2026-03-23 04:11:13
This article analyzes the historical performance of investing $1,000 in Xortx Therapeutics Inc (XRTX) over 1, 5, and 10 years, showing significant losses and underperformance compared to the S&P 500. It also provides an overview of Xortx Therapeutics, a late-stage clinical pharmaceutical company developing therapies for gout and kidney diseases, highlighting its pipeline, scientific rationale, and business model. The company's financial and regulatory profile, including its Nasdaq listing and efforts to regain compliance, are also discussed.
2026-03-21 21:09:36
XORTX Therapeutics (XRTX) significantly reduced its net loss to US$2.66 million in 2025 due to progress in late-stage clinical programs for gout and kidney diseases, with a New Drug Application (NDA) filing targeted within 12 months. Despite this financial improvement, the company's cash reserves dwindled, emphasizing the need for critical ongoing funding to manage regulatory and market risks. This information is derived from an AI-generated summary of their SEC 20-F Annual Report.
